GlassScriptPhysician profile
Yousef Joseph Usta
NPI 1962630962
$11,537.91
in general payments reported to CMS, 2019-2025
43 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $748 · 2021: $1,369 · 2022: $1,925 · 2023: $1,782 · 2024: $1,913 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,853 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,852.79 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,795.05 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,353.77 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $1,215.85 | 2019-2025 | |
| Janssen Biotech, INC. | $1,015.37 | 2019-2025 | Stelara, Tremfya, Remicade |
| Celgene Corporation | $545.90 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $382.39 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $369.77 | 2022-2025 | |
| Redhill Biopharma INC. | $369.61 | 2021-2022 | |
| Ucb, INC. | $280.17 | 2019-2021 | |
| Ardelyx, INC. | $254.69 | 2024-2025 | Ibsrela |
| Vivus LLC | $252.14 | 2019-2025 | Qsymia, Pancreaze |
| Ferring Pharmaceuticals INC. | $250.03 | 2019-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $219.73 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.40 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $196.57 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousef Usta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.